Clinicians treating patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer are navigating ...
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...
Hosted on MSN
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...
Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
– evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of ...
SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback